Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial.
暂无分享,去创建一个
Joon-Oh Park | S. Yun | Jong Hoon Kim | J. Kim | C. Yu | Tae Won Kim | Tae-You Kim | K. Jung | Keun-Wook Lee | B. Nam | J. S. Lee | H. Park | Y. Park | Ji Sung Lee | J. Baek | S. Kim | Y. Hong | J. Ahn | Seok-Byung Lim | Kyu-pyo Kim | J. E. Kim | Jin-hong Park | J. C. Kim
[1] M. Shakibaei,et al. Calebin A Potentiates the Effect of 5-FU and TNF-β (Lymphotoxin α) against Human Colorectal Cancer Cells: Potential Role of NF-κB , 2020, International journal of molecular sciences.
[2] M. Choti,et al. Association of Adjuvant Chemotherapy With Overall Survival in Patients With Rectal Cancer and Pathologic Complete Response Following Neoadjuvant Chemotherapy and Resection , 2018, JAMA oncology.
[3] H. Putter,et al. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] P. Quirke,et al. Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. , 2014 .
[5] Tae Hyun Kim,et al. Pathologic nodal classification is the most discriminating prognostic factor for disease-free survival in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection. , 2010, International journal of radiation oncology, biology, physics.